» Articles » PMID: 10688046

Muscle Weakness, Hyperactivity, and Impairment in Fear Conditioning in Tau-deficient Mice

Overview
Journal Neurosci Lett
Specialty Neurology
Date 2000 Feb 25
PMID 10688046
Citations 103
Authors
Affiliations
Soon will be listed here.
Abstract

Tau, one of the major neuronal microtubule-associated proteins (MAPs), is important for neuronal cell morphogenesis and axonal maintenance. Tau is also known to be a component of the paired helical filaments (PHFs) in Alzheimer's disease patients. Recently, mutations in the tau gene were found in a hereditary neurodegenerative disease called frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) which exhibits various neurological and neuropathological characteristics including PHF-like intracellular tau deposit formation. Currently, the phenotype of the disease is thought to be due to: (1) the toxicity of mutant tau molecules and and/or; (2) the loss of function of normal tau molecules in patients' brains. To test the latter hypothesis, we performed behavioral and neurological tests on tau-deficient mice. Tau-deficient mice showed muscle weakness in the wire-hanging test, hyperactivity in a novel environment, and impairment in the contextual fear conditioning. They also had a tendency to fall more easily in the rod-walking test. These phenotypes parallel some signs and symptoms of FTDP-17 patients. Our results show that the loss of tau protein may itself lead to some of the neurological characteristics observed in FTDP-17 patients.

Citing Articles

Mitochondrial Quality Control in Alzheimer's Disease: Insights from Models.

Ganguly U, Carroll T, Nehrke K, Johnson G Antioxidants (Basel). 2024; 13(11).

PMID: 39594485 PMC: 11590956. DOI: 10.3390/antiox13111343.


Cellular and pathological functions of tau.

Bravo C, Naguib S, Gan L Nat Rev Mol Cell Biol. 2024; 25(11):845-864.

PMID: 39014245 DOI: 10.1038/s41580-024-00753-9.


The disease-causing tau V337M mutation induces tau hypophosphorylation and perturbs axon morphology pathways.

Mohl G, Dixon G, Marzette E, McKetney J, Samelson A, Serras C bioRxiv. 2024; .

PMID: 38895329 PMC: 11185762. DOI: 10.1101/2024.06.04.597496.


Development of small-molecule Tau-SH3 interaction inhibitors that prevent amyloid-β toxicity and network hyperexcitability.

Roth J, Rush T, Thompson S, Aldaher A, Dunn T, Mesina J Neurotherapeutics. 2024; 21(1):e00291.

PMID: 38241154 PMC: 10903085. DOI: 10.1016/j.neurot.2023.10.001.


Prevalence of Concomitant Pathologies in Parkinson's Disease: Implications for Prognosis, Diagnosis, and Insights into Common Pathogenic Mechanisms.

Walker L, Attems J J Parkinsons Dis. 2023; 14(1):35-52.

PMID: 38143370 PMC: 10836576. DOI: 10.3233/JPD-230154.